Akeso Restructures MAb Manufacturing Deal as Joint Venture Becomes Connected Transaction

An announcement from Akeso, Inc. ( (HK:9926) ) is now available.

Akeso has updated the contractual framework governing the manufacturing of its monoclonal antibody products for its joint venture CTTQ-Akeso, which was established with partner Chia Tai Tianqing. Under a supplemental agreement effective 1 January 2025, CTTQ-Akeso will, in principle, source equal quantities of MAb products from both Akeso Biopharma and Nanjing Tianqing, reflecting a shared production arrangement between the two manufacturing partners. Because CTTQ-Akeso is no longer classified as an insignificant subsidiary, Chia Tai Tianqing and its 95%-owned Nanjing Tianqing have become connected persons at the subsidiary level, making the supplemental agreement a continuing connected transaction subject to Hong Kong listing rule disclosure and annual review requirements. Akeso acknowledged that this supplemental agreement should have been announced earlier and attributed the delay to an inadvertent oversight, and it has appointed Rainbow Capital as independent financial adviser to justify the longer-than-three-year term of the agreement, underscoring the company’s need to align its collaboration structures with ongoing regulatory compliance obligations.

The most recent analyst rating on (HK:9926) stock is a Hold with a HK$130.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.

More about Akeso, Inc.

Akeso, Inc. is a biopharmaceutical company focused on the research, development and manufacturing of monoclonal antibody (MAb) products, with production conducted through its subsidiary Akeso Biopharma and collaborations such as its joint venture CTTQ-Akeso in partnership with Chia Tai Tianqing.

Average Trading Volume: 7,025,771

Technical Sentiment Signal: Buy

Current Market Cap: HK$102.8B

See more insights into 9926 stock on TipRanks’ Stock Analysis page.